Article
A case of Ph+ acute lymphoblastic leukemia and EGFR mutant lung adenocarcinoma synchronous overlap: may one TKI drug solve two diseases?
BMC medical genomics - 8 Jul 2024
Zhang Qi, Zhou Jing-Dong, Ding Hao, Yang Lei, Lu Chao, Chu Ming-Qiang, Qian Jun, Zhang Ting-Juan
Abstract excerpt
BACKGROUND: Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) refers to ALL patients with t(9;22) cytogenetic abnormalities, accounting for about 25% of ALL. Lung adenocarcinoma (LUAD) is the most common pathological type of non-small-cell lung cancer, which has a frequency of approximately 45% cases with mutations in EGFR. Both Ph+ ALL and EGFR mutant LUAD are involved in the pathogenesis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.